Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia, Myeloid, Chronic-Phase 3Polycythemia Vera 2Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1

Interventions

Cyclophosphamide 125fludarabine phosphate 116Busulfan 98Peripheral Blood Stem Cell Transplantation 88Filgrastim 73Antilymphocyte Serum 72Tacrolimus 67Cytarabine 67Cyclosporine 64Mycophenolic Acid 63Methotrexate 57Radiotherapy 54fludarabine 52Whole-Body Irradiation 52Melphalan 49Imatinib Mesylate 41Azacitidine 35Methylprednisolone 34Etoposide 33Cord Blood Stem Cell Transplantation 30Granulocyte Colony-Stimulating Factor 28sargramostim 26Thiotepa 26Decitabine 21Alemtuzumab 21Clofarabine 20thymoglobulin 19Stem Cell Transplantation 19nilotinib 18Interferon-alpha 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × peginterferon alfa-2b × Myeloid × Clear all
NCT00415857 2018-08-21

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 3 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡